BridgeBio Oncology Therapeutics Inc.

NASDAQ:BBOT

Biotechnology

Healthcare
$1.86 -0.39%

-$0.03 today

Market cap
$149.27M
Beta
0.29
P/E (TTM)
-1.5
EPS (TTM)
-$4.95
52W Low $7.00High $14.87

Volume 0.37M

Average 0.37M

Cash Flow

Check whether earnings turn into cash.

Operating Cash Flow

-$113.89M

FY 2025 · Annual

Investing Cash Flow

$73.33M

FY 2025 · Annual

Financing Cash Flow

$383.40M

FY 2025 · Annual

+105.6% YoY

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(74)(3.52K)(41.69K)7.6M(134.04M)
Depreciation & Amortization0000610K
Deferred Income Tax00000
Stock-Based Compensation000271.57K5.87M
Change in Working Capital0015K(104.61K)6.43M
Accounts Receivables00000
Inventory00000
Accounts Payables000172.52K(1.84M)
Other Working Capital0015K(277.13K)8.27M
Other Non-Cash Items743.52K26.69K(8.53M)7.23M
Operating Cash Flow00(52.08M)(763.82K)(113.89M)
Capital Expenditures0000(606K)
Acquisitions (Net)00000
Purchases of Investments000(184M)(83.93M)
Sales of Investments0000157.86M
Other Investing Activities00000
Investing Cash Flow000(184M)73.33M
Debt Repayment000(209.85K)0
Common Stock Issued000187.25M395.72M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities000(578.55K)(12.32M)
Financing Cash Flow000186.46M383.4M
Effect of Forex Changes00000
Net Change in Cash00225K1.7M342.84M
Free Cash Flow00(52.49M)(763.82K)(114.5M)

Free Cash Flow

Net Income to FCF bridge

FY2025

= Net Income-$134.0M
+ D&A$610.0K
+ Stock-Based Comp$5.9M
+ Deferred Tax$0
+ Working Capital$6.4M
+ Other Non-Cash$7.2M
= Operating Cash Flow-$113.9M
- Capex-$606.0K
= Free Cash Flow-$114.5M

Analysis

FY2025 free cash flow is -$114.5M. FCF conversion is 85.4% of net income. Operating cash flow was -$113.9M, with capex of -$606.0K. The largest bridge item is Other Non-Cash at $7.2M.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
SC 13G/ASC 13G/A filingNov 13, 2026
10-QQuarterly reportNov 10, 2026
8-KCurrent reportNov 10, 2026
8-KCurrent reportNov 5, 2026
4Statement of changes in beneficial ownershipOct 23, 2026

Does BBOT generate free cash flow?

BridgeBio Oncology Therapeutics Inc. (BBOT) generated -$114.50M of free cash flow in fiscal 2025.

How much operating cash flow does BBOT produce?

Operating cash flow was -$113.89M, before capital expenditures of $606,000.00.